- Home
- MPB vs BBNX Comparison
MPB vs BBNX Comparison
Compare MPB & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- BBNX
- Stock Information
- Founded
- MPB 1868
- BBNX 2015
- Country
- MPB United States
- BBNX United States
- Employees
- MPB N/A
- BBNX N/A
- Industry
- MPB Major Banks
- BBNX Medical/Dental Instruments
- Sector
- MPB Finance
- BBNX Health Care
- Exchange
- MPB Nasdaq
- BBNX Nasdaq
- Market Cap
- MPB 467.7M
- BBNX 463.4M
- IPO Year
- MPB N/A
- BBNX 2025
- Fundamental
- Price
- MPB $25.39
- BBNX $11.14
- Analyst Decision
- MPB Buy
- BBNX Strong Buy
- Analyst Count
- MPB 2
- BBNX 6
- Target Price
- MPB $36.00
- BBNX $26.67
- AVG Volume (30 Days)
- MPB 127.4K
- BBNX 690.5K
- Earning Date
- MPB 04-28-2025
- BBNX 05-06-2025
- Dividend Yield
- MPB 3.15%
- BBNX N/A
- EPS Growth
- MPB 26.64
- BBNX N/A
- EPS
- MPB 2.90
- BBNX N/A
- Revenue
- MPB $177,648,000.00
- BBNX $65,123,999.00
- Revenue This Year
- MPB $19.07
- BBNX $29.49
- Revenue Next Year
- MPB $11.53
- BBNX $34.93
- P/E Ratio
- MPB $8.76
- BBNX N/A
- Revenue Growth
- MPB 9.01
- BBNX 442.93
- 52 Week Low
- MPB $19.20
- BBNX $8.89
- 52 Week High
- MPB $33.87
- BBNX $24.50
- Technical
- Relative Strength Index (RSI)
- MPB 48.00
- BBNX N/A
- Support Level
- MPB $23.78
- BBNX N/A
- Resistance Level
- MPB $25.51
- BBNX N/A
- Average True Range (ATR)
- MPB 1.08
- BBNX 0.00
- MACD
- MPB 0.15
- BBNX 0.00
- Stochastic Oscillator
- MPB 77.90
- BBNX 0.00
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.